Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note released on Thursday, January 18th.

A number of other research analysts have also recently commented on ACRS. Cantor Fitzgerald reissued a buy rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, September 26th. Zacks Investment Research raised Aclaris Therapeutics from a hold rating to a buy rating and set a $31.00 price objective for the company in a research note on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $41.80.

Aclaris Therapeutics (NASDAQ ACRS) opened at $19.10 on Thursday. Aclaris Therapeutics has a 52-week low of $18.46 and a 52-week high of $33.25. The company has a market cap of $575.93 and a P/E ratio of -8.84.

Several large investors have recently modified their holdings of ACRS. BlackRock Inc. increased its holdings in Aclaris Therapeutics by 28.4% in the 4th quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock worth $54,129,000 after buying an additional 485,146 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Aclaris Therapeutics by 147.6% in the 4th quarter. Bank of New York Mellon Corp now owns 272,404 shares of the biotechnology company’s stock worth $6,718,000 after buying an additional 162,389 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Aclaris Therapeutics in the 4th quarter worth about $200,000. Alps Advisors Inc. increased its holdings in Aclaris Therapeutics by 15.7% in the 4th quarter. Alps Advisors Inc. now owns 34,168 shares of the biotechnology company’s stock worth $843,000 after buying an additional 4,626 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Aclaris Therapeutics by 24.1% in the 4th quarter. Victory Capital Management Inc. now owns 73,501 shares of the biotechnology company’s stock worth $1,813,000 after buying an additional 14,290 shares in the last quarter. Hedge funds and other institutional investors own 92.47% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by BidaskClub” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/aclaris-therapeutics-acrs-cut-to-sell-at-bidaskclub.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply